We are creating some awesome events for you. Kindly bear with us.

International research team develops polymer that can kill 5 types of drug-resistant bacteria

International research team develops polymer that can kill 5 types of drug-resistant bacteria

According a press
from the Agency for Science, Technology and Research (A*STAR), an international
research team led by A*STAR’s Institute of Bioengineering and Nanotechnology (IBN) and IBM Research has developed a synthetic
molecule that can kill five deadly types of multidrug-resistant bacteria with
limited, if any, side effects. This study was also done in collaboration with
the University of North Dakota’s School of Medicine and Health Sciences, and
the First Affiliated Hospital of Zhejiang University’s College of Medicine. 

The new material could be developed into an antimicrobial
drug to treat patients with antibiotic-resistant infections. This finding was
reported in the scientific journal Nature Communications.

Bacteria resistance to antibiotics presents a serious global
health threat. Bacteria are beginning to develop resistance to the last-line
antibiotics, which are given only to patients infected with bacteria resistant
to available antibiotics.

According to the UK Review on Antimicrobial Resistance,
superbugs kill around 700,000 people worldwide each year. By 2050, 10 million
people could die each year if existing antibiotics continue to lose their

The alternatives to antibiotics being explored by the
research includes synthetic polymers. However, the antimicrobial polymers
developed so far are either too toxic for clinical use, not biodegradable or
can only target one type of bacteria. 

To address this problem, Dr Yi Yan Yang from IBN brought
together a multidisciplinary research team from the US, China and Singapore to
develop a new class of antimicrobial polymers called guanidinium-functionalized

They feature a unique killing mechanism that can target a
broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic
to human cells. 

The polymer binds specifically to the bacterial cell and is then
transported across the bacterial cell membrane into the cytoplasm, where it
causes precipitation of the cell contents (proteins and genes), resulting in
cell death. 

The team tested the polymers on mice infected with five
hard-to-treat multidrug-resistant bacteria: Acinetobacter baumanniiEscherichia coliKlebsiella
methicillin-resistant Staphylococcus aureu and Pseudomonas
. These superbugs commonly infect patients in the hospitals and can cause
systemic infections that lead to septic shock and multiple organ failure. The
results demonstrated that the bacteria were effectively removed from the mice
and no toxicity was observed. 

researchers further tested the effectiveness of the polymers on mice with
two types of systemic infections caused by superbugs: peritonitis (an infection
of the stomach’s inner lining) and lung infections from Pseudomonas
. The polymers eliminated the bacterial infections in both groups
of mice with negligible toxicity.  

determine whether the bacteria will develop any resistance to the polymer, the
team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute
of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research
– Almaden to perform genomic analysis. They found that the bacteria did not
show any resistance development even after multiple treatments with the

Dr Yi Yan Yang, Group Leader at IBN said, “We have
demonstrated the first
example of a biodegradable synthetic macromolecule with broad-spectrum
antimicrobial activity in mice, unique killing mechanism and no toxicity. Once
the polymer finishes its job of killing the bacteria, it will be
naturally degraded after three days and will not remain in the
body. This antimicrobial agent shows great promise for the treatment and
prevention of multidrug-resistant systemic infections.” 

“This study illustrates the potential for this new research
field we denote as ‘macromolecular therapeutics’ to create entirely new
classes of treatments for multiple diseases,” said Dr James Hedrick,
Distinguished Research Staff Member, IBM Research – Almaden, San Jose,
California. “In 2016, we demonstrated the efficacy of synthetic polymers to
combat deadly viral diseases. The current research for treating bacterial infections
rounds out our ability to someday treat a spectrum of infectious diseases with
a single, new type of mechanism without the onset of resistance,” he

IBN and IBM are now seeking collaborations with
pharmaceutical companies to develop the polymers into an antimicrobial
treatment for patients.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend